Call Girls Jayanagar Just Call 7001305949 Top Class Call Girl Service Available
Terapia sistémica en cáncer de testículo
1. Systemic therapy in testicular cancer
Mauricio Lema Medina MD
Clínica de Oncología Astorga, Clínica SOMA, Medellín
Simposio ACHO GU, Septiembre 23-24 de 2016, Bogotá
2. Mauricio Lema <mauriciolema@yahoo.com>Togarciaj4@ccf.org
Today at 7:36 AM
Hola Jorge, espero que estés bien. Te escribo para pedirte permiso para usar tu conferencia de cáncer de
testículo de 2012 que diste en Medellín, que creo es la mejor conferencia que he escuchado sobre GCTs.
Tengo que hablar del tema, y voy a tomarla como base.
Te agradezco que me autorices su uso (con crédito, por supuesto).
Un abrazo,
Mauricio Lema Medina MD
Garcia, M.D. Jorge A <GARCIAJ4@ccf.org>ToMauricio Lema
Today at 8:30 AM
Claro Mauricio
Si necesitas algunas otras slides me avisas
Un abrazo
Jorge
4. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
5. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
6. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
7. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
8. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
9. Not all Testis Cancers are the same
Seminoma
- No AFP
- Spurious elevations of HCG
- Path must have 100% + seminoma cells
- Radiotherapy or chemotherapy (recently)
Courtesy of Jorge A. García
10. Not all Testis Cancers are the same
Non-Seminoma
- Any serum marker
- Path could be mixed
- Observation of RPLND
Courtesy of Jorge A. García
11. Non-Seminoma
- % Embryonal component
- Lymphovascular invasion
- Paratesticular involvement
Seminoma
- Tumor size (> 4cm)
- Retetestis invasion
Pathological Features & Relapse
Courtesy of Jorge A. García
12. Stage I
Stage IIa
- Microscopic
- LNs < 2cm
Stage IIb
- LNs 2-5cm
Stage IIc (LNs > 5cm) = Advanced disease
Early Testis Cancer Staging
Courtesy of Jorge A. García
13. Observation/surveillance
- 15% risk of occult disease
Radiotherapy
Chemotherapy with Carboplatin (only scenario where
this agent is accepted in testis cancer)
Treatment Options for Stage I Seminoma
Courtesy of Jorge A. García
14. The Argument for Carboplatin for Stage I Seminoma
Carboplatin is the most effective way to prevent relapse
Carboplatin is associated with minimal acute toxicity
Radiation therapy is associated with unacceptable late
toxicity
The risk of late complications from single agent carboplatin
is hypothetical whereas the risk of late complications from
radiation therapy is well documented
Carboplatin appears to reduce the risk of second primary
germ cell tumors
Courtesy of Jorge A. García
15. Stage I Seminomas: Outcomes in published reports
Management
Number of
Patients Relapse
Median Time To
Relapse
(range) 5-year DSS
Surveillance 1032 18.4% 99.6%
Carboplatin
(2 cycles)
660 2.0%
9 – 15 mo
(4 – 28)
100%
Radiation 4630 3.8%
13 – 26 mo
(1 – 102)
99.7%
Courtesy of Jorge A. García
16. EORTC/MRC Randomized Controlled Trial:
Single Dose of Carboplatin vs. Radiation
Arm 3-yr Relapse Rate
RT 4.1% (2.9 – 5.6)
Carbo (1 cycle) 5.2% (3.6 – 7.5)
Arm N Relapses 2 year
RFS
3 year
RFS
Seminoma
Deaths
RT 904 36 96.7%
(95.3 – 97.7)
95.9%
(94.4 – 97.1)
1
Carbo
(1 cycle)
573 29 97.7%
(96.0-98.6)
94.8%
(92.5 – 96.4)
0
RT Oliver, Lancet, 2005;366:293Courtesy of Jorge A. García
17. EORTC/MRC Trial: 1 cycle Carboplatin v. Radiation:
Relapse-Free Survival
RT Oliver, Lancet, 2005;366:293
Courtesy of Jorge A. García
18. Carboplatin: one or two cycles?
RT Oliver, Lancet, 2005;366:293Courtesy of Jorge A. García
20. Disability and toxicity during treatment:
Radiation vs. Carboplatin RCT
Radiation
- More missed work
- More moderate to severe
lethargy
- More dyspepsia
Carboplatin
- More thrombocytopenia
RT Oliver, Lancet, 2005;366:293Courtesy of Jorge A. García
22. Sperm count in Swedish clinical stage I testicular cancer
patients following modern adjuvant treatment.
Weibring K, Proc ASCO 2016, 4542
182 pts Stage I GCT
Surveillance: 28 pts
Single-dose carboplatin: 22 pts
BEP x1: 62 pts
RT: 70 ptsSperm Count over time
Courtesy of Jorge A. García
23. What’s wrong with radiation?
Burden of treatment
Secondary Cancers
Cardiovascular Dz
Deaths from digestive
diseases
24. Do the math
100 men with stage I seminoma
- 80-82 cured with orchiectomy
- 18-20 destined to relapse on surveillance
- 3-5 relapse after radiation
- 13-17 relapses prevented by radiation
- 6-13 cancers result from radiation
Courtesy of Jorge A. García
25. False Arguments Against Carboplatin
Claim: Relapses after radiation are above the diaphragm
so surveillance CT scans are not needed
Fact: In the RT vs. Carbo trial, 41% of relapses in the RT
arm were below the diaphragm
In the two large RCTs of radiation for seminoma, two
thirds of relapses presented with disease below the
diaphragm
Courtesy of Jorge A. García
26. False Arguments Against Carboplatin
Claim: Relapses after radiation are above the diaphragm
so surveillance CT scans are not needed
Fact: In the RT vs. Carbo trial, 41% of relapses in the RT
arm were below the diaphragm
In the two large RCTs of radiation for seminoma, two thirds
of relapses presented with disease below the diaphragm
Claim: Late relapses are a risk after carboplatin
Fact: Relapses more than five years after treatment have
been reported following RT but NOT following
carboplatin.
The latest relapse after 2 cycles carbo was at
28 months
Courtesy of Jorge A. García
27. False Arguments Against Carboplatin
Claim: Carboplatin isn’t good enough for GCTs – cisplatin is
needed
Fact: Disease specific survival is between 99.9% and 100%.
Two cycles of carboplatin results in a relapse rate of 2%
Courtesy of Jorge A. García
28. False Arguments Against Carboplatin
Claim: Carboplatin isn’t good enough for GCTs – cisplatin is
needed
Fact: Disease specific survival is between 99.9% and 100%.
Two cycles of carboplatin results in a relapse rate of 2%
Claim: Carboplatin causes secondary malignancies.
Fact: Carboplatin has been associated with secondary
leukemias in women treated for ovarian cancer but not at
the doses used for seminoma.
Courtesy of Jorge A. García
29. False Arguments Against Carboplatin
Claim: Carboplatin isn’t good enough for GCTs – cisplatin is needed
Fact: Disease specific survival is between 99.9% and 100%.
Two cycles of carboplatin results in a relapse rate of 2%
Claim: Carboplatin causes secondary malignancies.
Fact: Carboplatin has been associated with secondary
leukemiasin women treated for ovarian cancer but not at
the doses used for seminoma.
Claim: Modern radiation is safe
Fact: We have no long-term follow-up data on modern radiation
Courtesy of Jorge A. García
30. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
31. Summary: Radiation Therapy
Radiation therapy has been proven to result in substantial
late morbidity and mortality
The long-term safety of current radiation therapy which
uses lower doses and smaller fields remains unproven
The switch to lower doses and small radiation fields has
resulted in more infra-diaphragmatic relapses after
radiation
Courtesy of Jorge A. García
32. Summary: Carboplatin
Single-Agent Carboplatin is very well tolerated
Two cycles of single-agent carboplatin has resulted in the
lowest published relapse rates for stage I seminoma
One cycle of carboplatin results in equivalent relapse rates
to radiation therapy
With over 1200 patients treated with carboplatin in
published reports, only one unsalvageable relapse has
been reported
Whether or not single-agent carboplatin causes any
significant late morbidity or mortality remains unknown
Courtesy of Jorge A. García
33. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
34. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
35. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
36. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
38. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
39. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
40. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
41. Metastatic Low-Risk Seminoma
Carboplatin AUC 10
PET-CT day 17-22
CMR No CMR
Carboplatin AUC 10 x3* (total) Carboplatin AUC 10 x4* (total)
*Cycles when plt>75, and rising
CarPET: Carboplatin AUC 10 in metastatic seminoma – early PET scanning
can reduce the amount of treatment whilst maintaining outcome – A Phase
II Trial
Shamash J, Proc ASCO 2016, Abstract 4545
42. Metastatic Low-Risk Seminoma
Carboplatin AUC 10
PET-CT day 17-22
CMR No CMR
Carboplatin AUC 10 x3* (total) Carboplatin AUC 10 x4* (total)
*Cycles when plt>75, and rising
CarPET: Carboplatin AUC 10 in metastatic seminoma – early PET scanning
can reduce the amount of treatment whilst maintaining outcome – A Phase
II Trial
n=48
n=21 n=26
Median follow-up of 25.8 mo:
OS 100%
PFS: 97.1%
Shamash J, Proc ASCO 2016, Abstract 4545
43. Observation/surveillance
- 30% risk of occult RPL metastases
RPLND
Cisplatin-based chemotherapy
- BEP x1-2
Treatment Options for Stage I NSGCT
Courtesy of Jorge A. García
44. Clinical trials of adjuvant chemotherapy in
‘high-risk’ clinical stage I NSGCT (1)
Author / year # of pts. Treatment Relapse (median f/u)
Oliver, 1992 22 BEP x 2 5% (1 pt) at 43
months; 1 relapse at
6m w/ chemo
response, then
relapse/death
Abratt, 1994 20 BEP x 2 0% at 31 months
Cullen, 1996 114 BEP x 2 1.7% (2 pts) at 4
years; 1 PD/death; 1
w/o GCT on retrosp.
review
Courtesy of Jorge A. García
45. Clinical Trials of adjuvant chemotherapy in
‘high-risk’ clinical stage I NSGC T (2)
Author / year # of pts. Treatment Relapse (median f/u)
Pont ‘96 29 BEP x 2 6.9% (2 pts) at 79
months - 1 mature teratoma
s/p sg-> NED; 1 embryonal
w/chemo response, then
relapse/death
Chevreau ‘97 38 BEP x 2 (33 pts.) 0% at 36 months
PVB x 2 (5 pts.)
Studer, 2000 59 BEP x 2 (39pts.) 3.3% (2 pts) at 93
PVB x 2 (20 pts.) months; 1 mature teratoma
resected at 22m; 1 stage II
seminoma at 7.5yrs.
Courtesy of Jorge A. García
46. Acute and Long-term AEs in Adjuvant Chemo Trials
Hematologic: G3 leukopenia (3.5%, 18%, 24%); no other
significant toxicity
GI: G3 emesis (27%, 13%); G2 Alopecia and G1Tinitus
--------------------------------------------------------------------------------------
Fertility: no change in pre- vs. post-sperm density/motility in two
studies; 2 others with 1-2 pts. with azoospermia (not different
than controls in one study)
Lung function: no change in PFTs in 2 studies
Audiometry: high-tone hearing loss (12%, 5%)
No 11q23 (etoposide-induced) AML reported
Courtesy of Jorge A. García
47. Case 2: 23 year-old patient undergoing
BEP cycle #2 for early-stage GCT
Page 47
48. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
49. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
50. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
51. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
52. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
53. Advanced Germ Cell Tumors
Defined as Stage IIC or higher
- Any pT/Tx N3 (>5cm) M0
Overall CR’s 70-80%
Poor outcome 20-30%
Identification by risk groups
- International Germ Cell Cancer
Collaborative Group (IGCCCG)
Courtesy of Jorge A. García
54. International Germ Cell Cancer
Collaborative Group (IGCCCG)
I – triple C – entre Gs
Page 54
55. Risk Assessment of Advanced Disease (IGCCCG)
NSGCT - Good Prognosis
Testis or RP primary, AND
No nonpulmonary visceral metastases, AND
Good Markers including all the following:
- AFP < 1,000 ng/ml
- HCG < 5,000 IU/L (1,000 ng/ml)
- LDH < 1.5 x upper limit of normal
56% of nonseminomas
5-year PFS 89%
5-year OS 92%
Courtesy of Jorge A. García
56. Risk Assessment of Advanced Disease (IGCCCG)
NSGCT - Intermediate Prognosis
Testis or RP primary, AND
No nonpulmonary visceral metastases, And
Intermediate Markers including any the following:
- AFP >= 1,000 ng/ml and <= 10,000 ng/ml
- HCG >= 5,000 IU/L and <= 50,000 IU/L
- LDH >= 1.5 x Nl and <= 10 x Nl
28% of nonseminomas
5-year PFS 75%
5-year OS 80%
Courtesy of Jorge A. García
57. Risk Assessment of Advanced Disease (IGCCCG)
NSGCT - Poor Prognosis
Mediastinal primary, OR
Nonpulmonary visceral metastases, OR
Poor Markers including any the following:
- AFP >= 10,000 ng/ml
- HCG >= 50,000 IU/L (10,000 ng/ml)
- LDH >= 10 x upper limit of normal
16% of nonseminomas
5-year PFS 41%
5-year OS 48%
Courtesy of Jorge A. García
58. Risk Assessment of Advanced Disease (IGCCCG)
Seminoma
Good Prognosis
Any primary site, AND
No nonpulmonary visceral metastases, AND
Normal Markers
- 90% of seminomas, 5-year PFS 82%, 5-year OS 86%
Intermediate Prognosis
Any primary site, AND
Nonpulmonary visceral metastases, AND
Normal Markers
- 10% of seminomas, 5-year PFS 67%, 5-year OS 72%
Courtesy of Jorge A. García
60. Treatment for Good-Risk Advanced
Germ Cell Tumors
Cisplatin, Etoposide and Bleomycin (PEB) x 4
- Standard of Therapy since the late 80’s
PVB x 4 v PEB x 4 (E = Etoposide or VP-16)
- Randomized Phase III study of 244 patients
- CR 74% v 83% with or without surgery (P not significant)
- High-Tumor Volume (n=157) - CR 61% v 77% (P < 0.05)
- 5-year OS greater with PEB (P < 0.048)
- Less toxicities with PEB
- Paresthesias (p= 0.02)
- Abdominal Cramps (p= 0.0008)
- Myalgias (p= 0.00002)
Williams SD, et al. NEJM 316, 1987
Courtesy of Jorge A. García
61. Clinical Trials for Good-Risk Advanced
Germ Cell Tumors
Goal is to decrease toxicity
Are 4 cycles of PEB better than 3 ??
Administration over 5 days vs. 3 days ??
Bleomycin or not ??
Carboplatin vs. Cisplatin ??
Courtesy of Jorge A. García
62. Are 4 cycles of PEB better than 3 ??
Adapted from Einhorn LH, et al. JCO 7:387-391.1989.
de Wit R, et al. JCO 19:1629-1640. 2001.
Institution n Regimen Response Relapses Toxicities
PEB x 4 6% Relapse
SECSG 184 v 98%
PEB x 3 92% NED
74.9% v 73% (p= 0.41) 2-year PFS
PEB x 4 2-year OS (90.4% v 89.4%)
EORTC 812 v (97% v 97.1%) HR 0.93
PEB x 3 HR 1.02 (80%CI 0.71-1.24)
(80%CI 0.61-1.73)
63. Administration Schedule:
Is it 5 days better than 3 days ?
R
A
N
D
O
M
I
Z
A
T
I
O
N
PEB x 3 for 3 days
(CDDP 50mg/m2 D1-2, VP-16 165mg/m2 D1-3
Bleomycin 30mg D1, D8, D15 for 3 cycles)
PEB x 3 for 5 days
(CDDP 20mg/m2 D1-5, VP-16 100mg/m2 D1-5
Bleomycin 30mg D1, D8, D15 for 3 cycles)
PEB x 3 + PE x 1 for 3 days
(CDDP 50mg/m2 D1-2, VP-16 165mg/m2 D1-3
Bleomycin 30mg D1, D8, D15 for 3 cycles)
PEB x 3 + PE x 1 for 5 days
(CDDP 50mg/m2 D1-2, VP-16 165mg/m2 D1-3
Bleomycin 30mg D1, D8, D15 for 3 cycles)
n = 812
de Wit R, et al. JCO 19:1629-1640. 2001
Courtesy of Jorge A. García
64. Administration Schedule: Is it 5 days better than 3 days ?
3days (n = 333) 5 days (n = 329)
_____________________ _______________________
Variable No. % No. % p
Complete Response 247 74.1% 240 72.9% 0.718
(Chemo + Surgery)
2 year PFS 89.7% 88.8%
HR 1.05 (80% CI 0.78-1.41)
96.4% 97.5%
2 year OS
HR 0.80 (80% CI 0.4-1.42)
Adapted from de Wit R, et al. JCO 19:1629-1640. 2001
65. What is the Role of Bleomycin ?
ECOG (Loehrer PJ, et al. JCO 13:470-476, 1995)
- Randomized 178 pts to PEB x 3 v PE x 3 (American regimen)
- Complete Response 94% v 88% (p= not significant)
- Greater Treatment Failures in PE arm (post-chemo masses and relapses
from CR) (p= 0.004)
- Overall Survival 95% v 86% (p= 0.01)
EORTC (de Wit R, et al. JCO 15:1837-1843,1997)
- Randomized 395 pts to PEB x 4 v PE x 4 (European regimen)
- Complete Response 95% v 87% (p= 0.0075)
- TTP (p= 0.136) and Overall Survival (p= 0.262)
- Neurotoxicity and Pulmonary Toxicity greater with PEB
(p< 0.001)
Courtesy of Jorge A. García
66. Carboplatin instead of CDDP ?
MSKCC (Bajorin DF, et al. JCO 11:598-606, 1993)
- Multicenter Phase III - Randomized 270 pts to EP x 4 v EC x 4
- Complete Response 90% v 88% (p= 0.32)
- Event-Free Survival inferior for EC arm (p= 0.02)
- Relapse-Free Survival inferior for EC arm (p= 0.005)
- No difference in Overall Survival (p= 0.52)
MRC/EORTC (Horwich A, et al. JCO 15:1844-1852, 1997)
- Multicenter Phase III - Randomized 598 pts to PEB x 4 v CEB x 4
- Complete Response 94.4% v 87.3% (p= 0.009)
- 1-year failure-free rates 91% (95% CI, 88%-94%) and 77%
(95% CI, 72%-82%) p < 0.001
- Overall Survival 97% v 90% (p= 0.003)
Courtesy of Jorge A. García
69. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
70. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
71. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
72. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
73.
74. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
75. Clinical Trials for Intermediate and Poor-Risk
Advanced Germ Cell Tumors
Goal is to Increase Efficacy
Exploiting agents used in the salvage setting
Evaluation of the role of dose escalation
Alternating non-cross resistant Chemotherapy
Evaluation of HDC-PSCT as in the salvage setting
Courtesy of Jorge A. García
76. Poor Risk – Advanced NSGCT’s
Suboptimal outcome of poor-risk patients
- 5-year PFS 41% and 5-year OS 48%
Goal is to increase efficacy
- Alternating non-cross-resistant chemotherapy
- Dose escalation
- Exploiting agents used in the salvage setting including
HDCT-ASCT
Single Institutional Trials (MSKCC)*
- VAB-6 and VAB-6 + EP (CR’s = 45% and 46%)
- VAB-6 + HDCT(EC)-ASCT (CR = 56%)
- VIP X4 vs.VIPX2 > HDCT (EC)-ASCT (CR = 53%)
*Motzer et al. J Clin Oncol 1997;15:2546-2552.
Courtesy of Jorge A. García
77.
78. Eligibility/Stratification
• Modified IGCCCG*
- Poor vs. Intermediate
• Center (CALGB-MSKCC-
SWOG and ECOG)
Randomization(N=218)
Cisplatin 20 mg/m2 daily x 5 days
Etoposide 100 mg/m2 daily x 5 days
Bleomycin 30 mg days 1, 8, and 15
G-CSF days 5 mcg/kg days 7-16 excluding
bleomycin days
Carboplatin 600 mg/m2 daily x 3 days
Etoposide 600 mg/m2 daily x 3 days
Cyclophosphamide 50 mg/kg x 3 days
Autologous stem cells day 5
Growth factor support
BEP X2 – HDCT (CEC) X2
BEP X4
Target accrual was 218 pts to detect an improvement of 20% in CR at 1 year
with an alpha=0.05 and 80% power
*Motzer et al. J Clin Oncol 1997;15:2546-2552.
Adapted from Bajorin DF, et al. Abstract 4510, ASCO 2006.
Intergroup Study of Poor-risk GCT
Courtesy of Jorge A. García
79. Outcome: Response Rate
BEP (%)
(n=111)
BEP + HD (%)
(n=108)
Complete response (CR) 55 56
CR to chemotherapy 46 48
CR to chemotherapy + Surgery 9 8
Incomplete response 44 43
PR – negative markers 5 10
1-year durable CR rate 48 52
Completion of C1-2 BEP 99 100
Completion of C3-4 BEP or HD-CEC 88 77
Adapted from Bajorin DF, et al. Abstract 4510, ASCO 2006.
84. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
85. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
86. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
87. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
88. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
89. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
90. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
91. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
92. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
93. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
94. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
95. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
96. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
97. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
98. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
99. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
100. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
101. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
102. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
103. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
104. Mature results of the GETUG 13 phase III trial in
poor-prognosis germ-cell tumors
Fizazi K, Proc ASCO 2016, Abstract 4504
105. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
High-Risk (or Modified Intermediate-
Risk GCT_ LDH greater 3x ULN)
Paclitaxel 120 mg/m2, d1, d2
Ifosfamide/MESNA 1200 mg/m2, d1-d5
Cisplatin 20 mg/m2, d1-d5
106. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
High-Risk (or Modified Intermediate-
Risk GCT_ LDH greater 3x ULN)
Paclitaxel 120 mg/m2, d1, d2
Ifosfamide/MESNA 1200 mg/m2, d1-d5
Cisplatin 20 mg/m2, d1-d5
MESNA 120 mg/m2 30 minutes Ifosfamide, d1-d5
Dexamethasone 20 mg in the night before and morning of Paclitaxel
Anti H1/H2 before Paclitaxel
5-HT3 antagonist daily
Aprepitant on d4-d6
Dexamethasone 12 mg/d on d3-d7
Pegfilgrastim 6 mg on d6 or d7
Levofloxacin 500 mg/d on d7-d13
107. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
High-Risk (or Modified Intermediate-
Risk GCT_ LDH greater 3x ULN)
Paclitaxel 120 mg/m2, d1, d2
Ifosfamide/MESNA 1200 mg/m2, d1-d5
Cisplatin 20 mg/m2, d1-d5
MESNA 120 mg/m2 30 minutes Ifosfamide, d1-d5
Dexamethasone 20 mg in the night before and morning of Paclitaxel
Anti H1/H2 before Paclitaxel
5-HT3 antagonist daily
Aprepitant on d4-d6
Dexamethasone 12 mg/d on d3-d7
Pegfilgrastim 6 mg on d6 or d7
Levofloxacin 500 mg/d on d7-d13
If ANC less than 1000 or Plat less than 90,000/uL on d1, CT was delayed 1 week
108. Paclitaxel,
Ifosfamide, and
Cisplatin Efficacy for
First-Line Treatment
of Patients With
Intermediate- or
Poor-Risk Germ-Cell
Tumors
Feldman DR, JCO, 2016
High-Risk (or Modified Intermediate-
Risk GCT_ LDH greater 3x ULN)
109. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
110. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
111. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
112. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
113. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
114. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
115. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for
First-Line Treatment of Patients With
Intermediate- or Poor-Risk Germ-Cell Tumors
Feldman DR, JCO, 2016
116. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
117. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
118. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
119. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
120. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
121. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
122. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
123. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
124. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
125. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
126. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
127. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
128. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
129. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
130. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
131. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
132. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
133. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
134. High-dose Chemotherapy and Autologous Peripheral-
Blood Stem Cell Transplant for Relapsed Metastatic
Germ-Cell Tumors: The Indiana University Experience.
Adra N, Proc ASCO 2016, Abstract 4505
135. Case 4
Page 135
Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
136. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
137. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
138. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
139. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
140. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
141. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
142. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
143. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
144. Bosl G, Warde P, Heidenreich A, ASCO 2016: Testicular Cancer – a Multidisciplinary Case Based Discussion
145. Risk Assessment of Residual Masses after
Chemotherapy for Seminoma
Observed in 60-85%
20-25% with (+) masses have residual malignancy
42% of residual mass > 3cm will have viable malignant cells and
should undergo surgery
Masses < 3cm can be observed
PET has been shown to be a predictor for malignancy:
(De Santis M, et al. JCO 19, 2001)
Predicting: 96% of masses < 3cm / 100% of masses > 3cm
Courtesy of Jorge A. García
146. Risk Assessment of Residual Masses after
Chemotherapy for NSGCT
Observed in 30-40%
15% with (+) masses have viable malignant cells
Histology is a predicting factor for survival:
- Carcinoma 15% with CR 60-70%
- Teratoma 35% with CR 85%
- Necrosis/Fibrosis 50% with CR 85-90%
Role of Surgery
Role of Chemotherapy post-surgery
Courtesy of Jorge A. García
147. Viable Cells After Chemotherapy for NSGCT
International Study Group
Multivariate Analysis of Survival
PFS OS
Unfavorable Prognostic Factors Risk Ratio 95 % CI P Risk Ratio 95% CI P
Incomplete surgery 2.75 1.51 – 4.98 <.001 3.82 1.94 – 7.52 <.001
Viable malignant cells > = 10 2.25 1.28 – 3.94 .005 3.31 1.62 – 6.78 .001
Poor or intermediate IGCCC 2.58 1.34 – 4.97 .005 3.22 1.32 – 7.82 .01
Prognostic Index
5 – Year PFS 5 – Year OS
Risk Group
No of Adverse
Factors
Patients
(%) % 95% CI % 95% CI
Favorable 0 22 90 79 - 100 100
Intermediate 1 40 76 65 – 87 83 73 - 93
Poor >= 2 38 41 28 - 54 51 37 - 65
Adapted from Fizazi K, et al. JCO 19, 2001
- 238 pts with viable malignant cells in their resected specimen
- 5 year PFS and OS = 64% and 73%
Courtesy of Jorge A. García
148. Summary of Management for Advanced Germ Cell
Tumors
Stratification by IGCCCG
Good-risk
- PEB x 3 (if Pulmonary toxicity) >PE x 4
Intermediate-risk
- PEB x 4 v Clinical Trial
- VIP-TIP
Poor-risk
- PEB x 4 v Clinical trial
- VIP-TIP
Courtesy of Jorge A. García
149. Summary of Management for Advanced
Germ Cell Tumors
Salvage Therapy
- VIP - TIP - HDCT/PSCT
Post-chemotherapy residual masses
- Observation if <3cm (seminoma)
- Resection if >3cm (seminoma)
- Resection in NSGCT vs. Salvage chemotherapy (poor-risk)
Courtesy of Jorge A. García